<DOC>
	<DOCNO>NCT01450046</DOCNO>
	<brief_summary>The Principal Investigator believe Vitamin E δ-Tocotrienol slow progression pancreatic cancer cell . Therefore , investigator must determine safety tolerability Vitamin E δ-Tocotrienol healthy participant administer cancer patient . The investigator give participant dose to1600 mg twice day , exceed 3200 mg total 14 consecutive day .</brief_summary>
	<brief_title>Vitamin E δ-Tocotrienol Multiple Dose Healthy Subjects</brief_title>
	<detailed_description>Participants accrue cohort three . The decision dose escalate make Cohort Review Committee ( CRC ) base safety last subject current cohort complete Study Treatment Period . The study consist follow procedure : - Pre-Treatment Period : The screening period must occur within 7 day dose . - Study Treatment Period ( 14 day ) : Vitamin E δ-Tocotrienol administer orally twice daily 14 consecutive day - Post-Treatment Period : Subject return study site 7 day dose Vitamin E δ-Tocotrienol end-of-treatment assessment . On day 8 ( ± 2 day ) last dose study drug , investigator obtain follow-up information . Any serious adverse event ( SAEs ) present 7 day last dose possibly related study drug follow resolution , stabilization , initiation treatment confound ability assess event .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>Equal great 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Adequate organ function : Serum creatinine ≤1.5 mg/dL calculate creatinine clearance ≥60 mL/min . Bilirubin ≤ intuitional upper limit normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within institutional normal range Absolute neutrophil count ( ANC ) ≥1000mm³ Platelet count ≥100,000mm³ Has capability understand informed consent document sign informed consent document Sexually active participant ( male female ) must use medically acceptable method contraception course study . Women childbearing potential must negative pregnancy test screening . Able understand comply requirement protocol receive investigational therapy ( investigational therapy study ) Have receive investigational therapy within 30 day prior first dose study drug Patients unable swallow capsule Patients prior malignancy , squamous basal cell carcinoma , unless disease free ≥ 5 year Have prior major surgery within 30 day prior first dose study drug The patient active infection fever &gt; 38.5C within 3 day prior first dose study drug . Have uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Unable unwilling stop taking vitamin , herbal remedy , nonprescription medication Pregnant breastfeed Unable unwilling abide study protocol cooperate fully investigator designee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>GI</keyword>
	<keyword>prevention</keyword>
	<keyword>vitamin E</keyword>
</DOC>